Strategies to achieve more effective and less-toxic CAR-T therapy

In recent years using genetically modified T cell has been known as a rapid developing therapeutic approach for hematological disorders. Chimeric antigen receptors (CARs) are genetically engineered receptors expressed on T cells that are specifically designed for the turmeric antigen of our interest in order to T cell activation. In fact, T cells presenting CAR have the potential of proliferating and maintaining in addition to sustained functional immunity in recipient. One of the main issues in this field is the enhancement of CAR T cell safety, effectiveness, and specificity. In the field of tumor therapy effectiveness improvement, criteria such as T cell gene modification and expansion protocols, CAR T cell injection dosage, lymphdepletion chemotherapy, etc., are extremely crucial. On the other hand, approaches such as combination of T cell therapy and immunomodulatory agents that block pathways involved in tumor development could have a significant effect on development of CAR T cell therapy outcome. Finally, as there are various limitations in the individualized T cell therapy process; many studies focused on universal and off-the-shelf allogeneic T cell drugs development with more efficient and available manufacturing process. In this review, we discuss a number of important studies that focused on enhancement of CAR T cell therapy effectiveness.

کلیدواژه ها:

Cell therapy ، Effective strategies ، Loss of toxicity ، CAR-T